FDA
-
-
-
-
-
-
-
Regeneron Pharma (REGN) PT Lowered to $860 at Wolfe Research
-
-
-
-
-
-
-
Regeneron Announces Agreement with U.S. Government to Help Lower Drug Costs for American Patients and Will Provide Innovative New Gene Therapy for Free in the U.S.
-
-
-
-
-
-
-
Dupixent® (dupilumab) Approved in the EU as the First Targeted Medicine to Treat Young Children with Chronic Spontaneous Urticaria (CSU)
-
-
-
-
-
-
-
Barclays Starts Regeneron Pharma (REGN) at Overweight
-
-
-
-
-
-
-
FDA accepts Regeneron's garetosmab application for priority review
-
-
-
-
-
-
-
Regeneron to present EYLEA HD data at Angiogenesis meeting
-
-
-
-
-
-
-
Regeneron and Tessera Therapeutics to Jointly Develop TSRA-196, an Investigational Gene Editing Therapy for Alpha-1 Antitrypsin Deficiency (AATD)
-
322,950 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

